Christina Bennett, MS

Researchers conducted gene expression analyses on prostate cancer tumor samples from World Trade Center first responders and general population patients to see if there were any differences between the two.

A new study looked at targeted vs nontargeted therapy in real world patients with renal cell carcinoma.

The TOPACIO trial tested the PARP inhibitor niraparib plus pembrolizumab in women with triple-negative breast cancer.

Nivolumab had limited efficacy against previously untreated brain metastases in patients with metastatic renal cell carcinoma, according to recent trial results.

This study adds to the evidence that the decline in access to local care due to the shuttering of rural hospitals and community cancer clinics adversely affects cancer patients.

A new study reinforces the need for universal mismatch repair protein immunohistochemistry screening of tumors from endometrial cancer patients, as well as germline genetic testing in accordance with guidelines.

A same-day biopsy program for women helped reduce disparities related to age, race, and insurance type in breast cancer care.

Researchers conducted a cost-effectiveness analysis on the two FDA-approved CAR T-cell therapies for diffuse large B-cell lymphoma.

A study in the Journal of the National Cancer Institute evaluated responses in men vs women to combination chemotherapy and a PD-1 or PD-L1 inhibitor.

A study in JAMA Oncology evaluated re-administration of immune checkpoint blockade in cancer patients who experienced a grade 2 or higher immune-related adverse event.

Researchers tested whether prophylactic irradiation after a chest wall procedure would benefit patients with malignant pleural mesothelioma.

A worldwide crowd innovation contest incentivized international programmers to create automated AI algorithms for an area of radiation oncology.

The bar for the standard of care among patients with advanced renal cell carcinoma is set high as various promising combination therapies recently received FDA approval.

The findings further validate the initial 2015 findings that a five-fraction SBRT schedule is appropriate for patients with centrally located NSCLC.

The results of a new study add to the list of benefits seen with exercise among breast cancer survivors: reducing the risk of cardiovascular disease.

Researchers evaluated whether breast cancer patients with hypothyroidism at diagnosis or who develop it later have an increased risk of recurrence or death.

A review and meta-analysis in JAMA Oncology evaluated the incidence of treatment-related adverse events in patients receiving PD-1 or PD-L1 therapy.

The phase II KEYNOTE-158 basket trial evaluated single-agent pembrolizumab in patients with previously treated advanced cervical cancer.

The investigators tested the agent in patients who had solid tumors with NTRK gene fusions that had developed resistance to other TRK inhibitors.

A study looked at whether a lung cancer risk prediction model could identify patients at high risk for lung cancer who could receive less frequent low-dose CT screening.

Research presented at AACR 2019 evaluated autologous mesothelin-targeted chimeric antigen receptor T-cell therapy in patients with malignant pleural disease.

A phase I trial evaluated the safety and efficacy of adding lymphodepletion to HER2-targeted T-cell therapy in patients with advanced HER2-positive sarcoma.

The results of a post-hoc exploratory analysis of the phase III ARIEL3 trial were promising.

The TWiST analysis of the phase III ENGOT-OV16/NOVA trial evaluated the time without symptoms or toxicity for niraparib vs placebo in patients with recurrent ovarian cancer.

The phase II trial evaluated dendritic cell–based immunotherapy with concomitant administration of chemotherapy vs chemotherapy alone.

Results of a phase II trial evaluating pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide were presented at SGO 2019.

Avelumab alone or with pegylated liposomal doxorubicin did not improve survival in this phase III trial, but a subgroup analysis showed promising findings.

Early results of the WISP trial, which is evaluating risk-reducing salpingo-oophorectomy vs salpingectomy with delayed oophorectomy, were presented in Honolulu.

In a phase IIIb trial, researchers evaluated the efficacy of an oral anticoagulant in cancer patients at high risk for venous thromboembolism.

A systematic review in JAMA Oncology examined the safety and efficacy of immune checkpoint inhibitors in advanced-stage cancer patients with HIV infection.